Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Gastrointestinal 4Breast 4Thoracic 2Sarcoma 2Other hematologic neoplasm 2Plasma cell 1Myeloid 1Lymphoid 1Gynecologic 1CNS 1

Conditions

Ovarian Neoplasms 1Carcinoma, Ovarian Epithelial 1Brenner Tumor 1

Interventions

Paclitaxel 153Carboplatin 123Bevacizumab 87Cisplatin 66pembrolizumab 58Taxes 51Gemcitabine 51liposomal doxorubicin 39Topotecan 37olaparib 31Immunoglobulin G 27Disulfides 26Cyclophosphamide 24Brachytherapy 22Docetaxel 21human papillomavirus vaccine, L1 type 16, 18 20niraparib 19Platinum 19Nivolumab 18Magnetic Resonance Spectroscopy 181,2-diaminocyclohexaneplatinum II citrate 18rucaparib 17durvalumab 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 16Doxorubicin 16Radiotherapy, Intensity-Modulated 14Radiation 13Albumin-Bound Paclitaxel 13fludarabine phosphate 12fludarabine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Reverse Transcriptase Polymerase Chain Reaction × Gynecologic × Clear all
NCT00408590 2024-01-16

Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Mayo Clinic

Phase 1 Completed
37 enrolled 8 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡